NeuroSense Therapeutics
NRSN
8 hedge funds and large institutions have $304K invested in NeuroSense Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
172% more capital invested
Capital invested by funds: $112K → $304K (+$192K)
0.18% more ownership
Funds ownership: 1.05% → 1.22% (+0.18%)
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$95.7K |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$26.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$8.66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$60.6K |
| 2 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
-$10.1K |
| 3 |
HF
HRT Financial
New York
|
-$10K |
| 4 |
Morgan Stanley
New York
|
-$2.02K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $129K | +$95.7K | +71,100 | New |
|
|
MIH
2
Meitav Investment House
Bene-Beraq,
Israel
| $91K | -$60.6K | -45,000 | -47% |
|
|
WP
3
Woodline Partners
San Francisco,
California
| $35.6K | +$26.4K | +19,581 | New |
|
4
Geode Capital Management
Boston,
Massachusetts
| $21.8K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $21.7K | +$8.66K | +6,432 | +117% |
|
|
6
Morgan Stanley
New York
| $2.73K | -$2.02K | -1,500 | -50% |
|
7
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $2K | – | – | – |
|
8
Qube Research & Technologies (QRT)
London,
United Kingdom
| $98 | – | – | – |
|
|
HF
9
HRT Financial
New York
| – | -$10K | -13,998 | Closed |
|
|
SRL
10
Scientech Research LLC
Jersey City,
New Jersey
| – | -$10.1K | -12,584 | Closed |
|
NRSN Hedge Fund Activity: Q1 2024 in Review
8 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q1 2024, worth a combined $304K — up 172% from $112K a quarter earlier.
Fund positioning in NRSN was balanced in Q1 2024: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $95.7K. The largest seller was Meitav Investment House, cutting an estimated $60.6K.
- 8 institutional investors held NeuroSense Therapeutics (NRSN) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $304K of NeuroSense Therapeutics stock for Q1 2024, up 172% quarter-over-quarter.
- 2 funds opened new NeuroSense Therapeutics positions in Q1 2024 and 2 closed out, a net change of 0 holders.
- The largest NeuroSense Therapeutics buyer in Q1 2024 was Renaissance Technologies, an estimated $95.7K added.
- The largest NeuroSense Therapeutics seller in Q1 2024 was Meitav Investment House, an estimated $60.6K sold.
Based on aggregated 13F filings for Q1 2024.